Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Digital work engagement among Italian neurologists.
Brigo F, Ponzano M, Sormani MP, Clerico M, Abbadessa G, Cossu G, Trojsi F, Colucci F, Tortorella C, Miele G, Spina E, Artusi CA, Carmisciano L, Servillo G, Bozzali M, Sparaco M, Leocani L, Lanzillo R, Tedeschi G, Bonavita S, Lavorgna L. Brigo F, et al. Among authors: sormani mp. Ther Adv Chronic Dis. 2021 Jul 20;12:20406223211029616. doi: 10.1177/20406223211029616. eCollection 2021. Ther Adv Chronic Dis. 2021. PMID: 34367544 Free PMC article.
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. Among authors: sormani mp. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP. Saccà F, et al. Among authors: sormani mp. Mult Scler. 2019 Aug;25(9):1263-1272. doi: 10.1177/1352458518790390. Epub 2018 Jul 25. Mult Scler. 2019. PMID: 30044207 Free article.
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group. Frau J, et al. Among authors: sormani mp. J Neurol. 2019 Oct;266(10):2440-2446. doi: 10.1007/s00415-019-09424-8. Epub 2019 Jun 17. J Neurol. 2019. PMID: 31209573
487 results